Nyrada Inc. announced Ian Dixon, PhD, MBA, MAICD will join the Board of the company. In addition, Dr. Graham Kelly will step down from the Board to focus on his role as Noxopharm CEO and Managing Director but will remain involved in Nyrada as a consultant. Dr. Dixon is a seasoned biotechnology entrepreneur with more than 20 years' experience in the Australian sector. Together with Dr Kelly, he founded Nyrada Inc. Ian is a co-inventor of the technology behind its Cholesterol Lowering Program, giving him deep expertise in the development of PCSK9 inhibitors. Dr. Dixon is also Chairman and founder of Altnia Group.